Foresee Pharmaceuticals Co (ROCO:6576) Other Current Receivables: NT$0.2 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6576 Foresee Pharmaceuticals Co Ltd ROCO:6576
61 GF Score
Price NT$81.60
GF Value NT$96.82
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Foresee Pharmaceuticals Co Other Current Receivables?

Foresee Pharmaceuticals Co ROCO:6576 -0.49% 61 Other Current Receivables is NT$0.2 Mil as of Dec. 2025. GuruFocus rates ROCO:6576 with a GF Score™ of 61/100 and a GF Value™ of NT$96.82 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Foresee Pharmaceuticals Co's Other Current Receivables for the quarter that ended in Dec. 2025 was NT$0.2 Mil.

Foresee Pharmaceuticals Co's quarterly Other Current Receivables declined from Jun. 2025 (NT$3.29 Mil) to Sep. 2025 (NT$1.03 Mil) but then stayed the same from Sep. 2025 (NT$1.03 Mil) to Dec. 2025 (NT$0.23 Mil).

Foresee Pharmaceuticals Co's annual Other Current Receivables increased from Dec. 2023 (NT$1.39 Mil) to Dec. 2024 (NT$3.81 Mil) but then declined from Dec. 2024 (NT$3.81 Mil) to Dec. 2025 (NT$0.23 Mil).

Foresee Pharmaceuticals Co Other Current Receivables Related Terms

Foresee Pharmaceuticals Co Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Foresee Pharmaceuticals Co's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Foresee Pharmaceuticals Co Other Current Receivables Chart

Foresee Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.32 1.39 3.81 0.23

Foresee Pharmaceuticals Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.81 4.88 3.29 1.03 0.23
ROCO:6576
61GF Score
Foresee Pharmaceuticals Co Ltd ROCO:6576
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Foresee Pharmaceuticals Co Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of NT$0.2 Mil mean?
Foresee Pharmaceuticals Co (ROCO:6576) has a Other Current Receivables of NT$0.2 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Foresee Pharmaceuticals Co and its competitors.
Is Foresee Pharmaceuticals Co's Other Current Receivables too high?
Foresee Pharmaceuticals Co's current Other Current Receivables is NT$0.2 Mil. Overall, Foresee Pharmaceuticals Co has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Foresee Pharmaceuticals Co's Other Current Receivables compare to ZTS?
Foresee Pharmaceuticals Co's Other Current Receivables of NT$0.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Foresee Pharmaceuticals Co and its competitors. Foresee Pharmaceuticals Co's current Other Current Receivables is NT$0.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foresee Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Foresee Pharmaceuticals Co (ROCO:6576) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$96.82, compared to a current price of NT$81.60 — trading 15.7% below its estimated fair value. The current Other Current Receivables is NT$0.2 Mil. Foresee Pharmaceuticals Co's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Foresee Pharmaceuticals Co (ROCO:6576), the current Other Current Receivables is NT$0.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Foresee Pharmaceuticals Co (ROCO:6576) Overvalued in 2026?

Based on GuruFocus' analysis, Foresee Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$81.60 is trading 15.7% below its estimated GF Value™ of NT$96.82. GuruFocus considers Foresee Pharmaceuticals Co to be Modestly Undervalued.

Key valuation signals for ROCO:6576:

  • Other Current Receivables: NT$0.2 Mil
  • GF Value™: NT$96.82 vs. price of NT$81.60 (15.7% below fair value)
  • GF Score™: 61/100 with 7 warning signs

No single metric tells the full story. See the ROCO:6576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Foresee Pharmaceuticals Co Business Description

Address No. 19-3, Sanchong Road, 9th Floor-2, Nangang District, Taipei, TWN, 115
Foresee Pharmaceuticals Co Ltd main activity is applying stabilized injectable formulation (SIF) platform technology to produce products for anticancer and treatment of chronic diseases. Its pipeline includes CAMCEVI (Leuprolide, FP-001), FP-014 (Triptorelin), Aderamastat (FP-025, MMP-12 Inhibitor), Linvemastat (FP-020, MMP-12 Inhibitor), and others. The Group operates business only in a single industry of new drug development, and all of its revenue is generated from Taiwan.
61GF Score

Get the complete analysis for ROCO:6576

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$81.60
Price
NT$96.82
GF Value